Background:
Pain is a common symptom in oncologic patients and its management is generally guided by pain
individually perceived by patients and expressed through self-reported scales. However, the utility of these tools is limited
because strongly dependent on patients’ opinions. For this reason, more objective instruments are desirable.
Objective:
In this overview scientific articles indicating potential markers to be used for pain management in cancer were
collected and discussed.
Methods:
research was performed on principal electronic scientific databases by using the words “pain”, “cancer”,
“markers” as “biomarkers” as the main keywords, and findings describing potential biomarkers for the management of
cancer pain were reported.
Results:
Studies on pain markers not specific for cancer typology (inflammatory, genetic, markers predicting response to
analgesic drugs, neuroimaging markers) and pain markers for specific types of cancer (bone cancer, breast cancer, lung
cancer, head and neck cancer, prostate cancer, cancer in pediatrics) are presented and commented.
Conclusion:
This overview supports the view of the involvement of inflammatory mediators in the mechanisms
underlying cancer pain. Up today only a few data from research on markers can help in the management of pain, except
for pro-inflammatory cytokines and other inflammatory indexes such as C-reactive protein (CRP). However, biomarkers
are a promising strategy useful to predict pain intensity and to purchase objective quantification of analgesic response in
guiding decisions on individual-tailored treatments in cancer patients.